The FDA first approved Auvelity in 2022 for major depressive disorder in adults. It combined two existing ingredients in a single tablet designed for this use. In a six-week depression study, the group taking Auvelity improved more than the group taking a placebo, a tablet without active medicine.
A difference was seen at the first weekly assessment, but this does not mean everyone feels better within a week. In April 2026, the FDA added approval for agitation associated with dementia due to Alzheimer’s disease. That decision followed studies of agitation symptoms and the return of symptoms after treatment withdrawal.
The two uses have different starting instructions. Neither approval establishes a UK product licence.